Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Program Overview

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Credit Expired
0.25 CE Credit(s)
Expires: October 10, 2022

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Faculty

Ison 300x400

Michael G. Ison, MD, MS

Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Zimmerman 300x400

Richard K. Zimmerman, MD, MPH, MS

Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Supporter Statement

Provider Statement

Disclosure of Financial Relationships


Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources